C. Robin Ganellin

Last updated

Charon Robin Ganellin
Born (1934-01-25) 25 January 1934 (age 90)
London, England
CitizenshipUnited Kingdom
Alma mater Queen Mary College
Known for Cimetidine
Scientific career
Fields Medicinal Chemistry
Institutions University College London

Charon Robin Ganellin FRS (born 25 January 1934) is a British medicinal chemist, and Emeritus Smith Kline and French Professor of Medicinal Chemistry, at University College London. [1] [2]

Contents

Ganellin has contributed much to the field of drug discovery and development. His most outstanding achievement was the discovery of cimetidine, a drug used to combat stomach ulcers, when he was working at Smith Kline and French. [3] He lives near London and is a professor at University College London.

Early life

Born in East London, Ganellin knew from an early age that his calling was chemistry. During his studies at Harrow County School for Boys, he developed a strong aptitude for science and maths, but his performance in language and history was lacking. Although he enjoyed biology and natural history above his other subjects, he was influenced to pursue a career in chemistry. As his father and his maternal uncle were chemists, he recognised that chemists could make a living. Uncertain if a career in biology was possible, he decided to become a chemist. He began his formal studies at Queen Mary College in London where he received his first degree, a bachelor of science in chemistry. He continued his studies at Queen Mary College, researching tropylium chemistry with Michael J.S. Dewar where he discovered how to isolate the tropylium cation from cyclooctatetraene. For this research, he was awarded his PhD in organic chemistry in 1958 at age 24.

Scientific work

In 1958, shortly after his PhD studies at Queen Mary College, Ganellin joined Smith Kline and French Laboratories in the UK where he began research in medicinal chemistry. [3] Two years after starting at SK&F, he went to the Massachusetts Institute of Technology where he performed his postdoctoral work with Arthur C. Cope. At MIT, he devised the first direct optical resolution of a chiral olefin using platinum complex chemistry. After a year at MIT, he returned to the UK to resume his work at SK&F. In 1966, he headed a landmark research team at SK&F, collaborating with Sir James Black researching histamine H2-receptor antagonists. This research eventually led to the discovery of Cimetidine, also known by its trademark name Tagamet which is currently produced by GlaxoSmith Kline. Cimetidine quickly garnered over one billion dollars in annual sales, making it the first blockbuster drug, [4] and it is currently listed by the World Health Organization as one of the most essential drugs.

Awards and achievements

Since graduating, Robin Ganellin has authored or co-authored over 260 scientific papers and is listed as inventor or co-inventor on over 160 US patents. He has served as the president of the IUPAC medicinal chemistry section, and for 10 years (until 2012) he was the chair of the subcommittee on medicinal chemistry and drug development. He has won many awards and commendations over the years, both for his work on cimetidine and his research in other areas of medicinal chemistry. He has received awards in medicinal chemistry from many organisations, such as the Royal Society of Chemistry, the American Chemical Society, the Society of Chemical Industry, the Society for Drug Research, the European Federation for Medicinal Chemistry, the Société Chimie Thérapeutique of France, and the Medicinal Chemistry Division of the Italian Chemical Society.

He was also inducted into the US National Inventors Hall of Fame in 1990 for his work on cimetidine. Ganellin currently serves as the Emeritus Professor of Medicinal Chemistry, although he is now partially retired.

Drugs List

[2104-81-6] Patent: 6-(4-Chlorophenyl)-2,2-dimethylpiperidin-4-one.svg
[2104-81-6] Patent:
  1. Icotidine
  2. Impromidine
  3. Cetiedil (enantiomers): [7]
  4. UCL 1608
  5. Oxmetidine
  6. Cimetidine
  7. UCL-1439
  8. Ciproxifan
  9. UCL-1390
  10. UCL 1684 (pharmacology)
  11. Donetidine
  12. Metiamide
  13. Burimamide
  14. 6-(4-Chlorophenyl)-2,2-dimethylpiperidin-4-one [2104-81-6] (stimulant & depressant properties): [5]
  15. 1-(2-diethylaminoethyl-2-(p-ethoxybenzyl)-2-indene (Ex 9, Nitazene type mimic): [8] [9] Patent: [10]

Related Research Articles

<span class="mw-page-title-main">Reagent</span> Substance added to a system to cause a chemical reaction

In chemistry, a reagent or analytical reagent is a substance or compound added to a system to cause a chemical reaction, or test if one occurs. The terms reactant and reagent are often used interchangeably, but reactant specifies a substance consumed in the course of a chemical reaction. Solvents, though involved in the reaction mechanism, are usually not called reactants. Similarly, catalysts are not consumed by the reaction, so they are not reactants. In biochemistry, especially in connection with enzyme-catalyzed reactions, the reactants are commonly called substrates.

H<sub>2</sub> receptor antagonist Class of medications

H2 antagonists, sometimes referred to as H2RAs and also called H2 blockers, are a class of medications that block the action of histamine at the histamine H2 receptors of the parietal cells in the stomach. This decreases the production of stomach acid. H2 antagonists can be used in the treatment of dyspepsia, peptic ulcers and gastroesophageal reflux disease. They have been surpassed by proton pump inhibitors (PPIs). The PPI omeprazole was found to be more effective at both healing and alleviating symptoms of ulcers and reflux oesophagitis than the H2 blockers ranitidine and cimetidine.

<span class="mw-page-title-main">James Black (pharmacologist)</span> Scottish doctor and pharmacologist (1924–2010)

Sir James Whyte Black was a Scottish physician and pharmacologist. Together with Gertrude B. Elion and George H. Hitchings, he shared the Nobel Prize for Medicine in 1988 for pioneering strategies for rational drug-design, which, in his case, lead to the development of propranolol and cimetidine. Black established a Veterinary Physiology department at the University of Glasgow, where he became interested in the effects of adrenaline on the human heart. He went to work for ICI Pharmaceuticals in 1958 and, while there, developed propranolol, a beta blocker used for the treatment of heart disease. Black was also responsible for the development of cimetidine, an H2 receptor antagonist, a drug used to treat stomach ulcers.

<span class="mw-page-title-main">Drug discovery</span> Pharmaceutical procedure

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.

<span class="mw-page-title-main">Lipinski's rule of five</span> Rule of thumb to predict if a chemical compound is likely to be an orally active drug

Lipinski's rule of five, also known as Pfizer's rule of five or simply the rule of five (RO5), is a rule of thumb to evaluate druglikeness or determine if a chemical compound with a certain pharmacological or biological activity has chemical properties and physical properties that would likely make it an orally active drug in humans. The rule was formulated by Christopher A. Lipinski in 1997, based on the observation that most orally administered drugs are relatively small and moderately lipophilic molecules.

<span class="mw-page-title-main">Medicinal chemistry</span> Scientific branch of chemistry

Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacy involved with designing and developing pharmaceutical drugs. Medicinal chemistry involves the identification, synthesis and development of new chemical entities suitable for therapeutic use. It also includes the study of existing drugs, their biological properties, and their quantitative structure-activity relationships (QSAR).

<span class="mw-page-title-main">Cimetidine</span> Medication

Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.

<span class="mw-page-title-main">The Frythe</span>

The Frythe is a country house set in its own grounds in rural Hertfordshire, just south of the village of Welwyn, about 30 miles north of London.

<span class="mw-page-title-main">Metiamide</span> Chemical compound

Metiamide is a histamine H2 receptor antagonist developed from another H2 antagonist, burimamide. It was an intermediate compound in the development of the successful anti-ulcer drug cimetidine (Tagamet).

A structural analog, also known as a chemical analog or simply an analog, is a compound having a structure similar to that of another compound, but differing from it in respect to a certain component.

<span class="mw-page-title-main">Burimamide</span> Chemical compound

Burimamide is an antagonist at the H2 and H3 histamine receptors. At physiological pH, it is largely inactive as an H2 antagonist, but its H3 affinity is 100x higher. It is a thiourea derivative.

<span class="mw-page-title-main">Antihistamine</span> Drug that blocks histamine or histamine agonists

Antihistamines are drugs which treat allergic rhinitis, common cold, influenza, and other allergies. Typically, people take antihistamines as an inexpensive, generic drug that can be bought without a prescription and provides relief from nasal congestion, sneezing, or hives caused by pollen, dust mites, or animal allergy with few side effects. Antihistamines are usually for short-term treatment. Chronic allergies increase the risk of health problems which antihistamines might not treat, including asthma, sinusitis, and lower respiratory tract infection. Consultation of a medical professional is recommended for those who intend to take antihistamines for longer-term use.

<span class="mw-page-title-main">Rhodanine</span> Chemical compound

Rhodanine is a 5-membered heterocyclic organic compound possessing a thiazolidine core. It was discovered in 1877 by Marceli Nencki who named it "Rhodaninsaure" in reference to its synthesis from ammonium rhodanide and chloroacetic acid in water.

<span class="mw-page-title-main">Ming-Ming Zhou</span>

Ming-Ming Zhou is an American scientist whose specification is structural and chemical biology, NMR spectroscopy, and drug design. He is the Dr. Harold and Golden Lamport Professor and Chairman of the Department of Pharmacological Sciences. He is also the co-director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System in New York City, as well as Professor of Sciences. Zhou is an elected fellow of the American Association for the Advancement of Science.

<span class="mw-page-title-main">Clorotepine</span> Antipsychotic medication

Clorotepine, also known as octoclothepin or octoclothepine, is an antipsychotic of the tricyclic group which was derived from perathiepin in 1965 and marketed in the Czech Republic by Spofa in or around 1971 for the treatment of schizophrenic psychosis.

<span class="mw-page-title-main">1-Indanone</span> Chemical compound

1-Indanone is the organic compound with the formula C6H4(CH2)2CO. It is one of two isomeric benzocyclopentanones, the other being 2-indanone. It is a colorless solid. 1-Indanone is a substrate for the enzyme indanol dehydrogenase.

Jonathan Baell is trained as an Australian medicinal chemist and is currently executive director, early leads chemistry at Lyterian Therapeutics in San Francisco. Prior to this, he was a research professor in medicinal chemistry at the Monash Institute of Pharmaceutical Sciences (MIPS), the director of the Australian Translational Medicinal Chemistry Facility and a Chief Investigator at the ARC Centre for Fragment-Based Design. He was President of the International Chemical Biology Society 2018-2021 and is currently chair of the board. His research focuses on the early stages of drug discovery, including high-throughput screening (HTS) library design, hit-to-lead and lead optimization for the treatment of a variety of diseases, such as malaria and neglected diseases.

Alfred Burger was a prominent chemist and a pioneer in medical chemistry. Burger was born in Vienna, the capitol of the Austro-Hungarian Empire, on 6 September 1905. He was the son of S. L. Burger and Clariss Burger.

<span class="mw-page-title-main">Holger Stark</span> German scientist and professor

Holger Stark (Prof. Dr. Dr. h. c.), born on September 15, 1962, is a German pharmacist and a Professor at Heinrich Heine University in Düsseldorf. Stark is a co-inventor of the active ingredient Pitolisant, the only histamine H3 receptor antagonist approved to date.

Professor Stephen Neidle is a British X-ray crystallographer, chemist and drug designer working at the UCL School of Pharmacy. His area of scientific research has been in nucleic acid structure and recognition, and the research topic of quadruplexes.

References

  1. ↑ Profile, ucl.ac.uk. Accessed 13 April 2024.
  2. ↑ Ganellin, C. Robin (2001). "Professor C. Robin Ganellin FRS". J. Chem. Soc., Perkin Trans. 1. 13 (13): i. doi:10.1039/B101382N.
  3. 1 2 Ganellin, C. Robin. Drug Discovery Today, Feb 2004, Vol. 9 Issue 4, p158, 3p
  4. ↑ "Pharmaceutical Sales 101: Me-Too Drugs by Jake Whitney – Guernica / A Magazine of Art & Politics". Archived from the original on 7 August 2008. Retrieved 3 December 2008.
  5. 1 2 Ganellin, C. R.; Spickett, R. G. W. (1965). "Compounds Affecting the Central Nervous System. I. 4-Piperidones and Related Compounds". Journal of Medicinal Chemistry. 8 (5): 619–625. doi:10.1021/jm00329a015.
  6. ↑ Ganellin Charon Robin & Spickett Robert Geoffr William, U.S. patent 3,067,204 (1962 to Smith Kline and French Laboratories Ltd).
  7. ↑ Roxburgh, Craig J.; Ganellin, C. Robin; Shiner, Mark A. R.; Benton, David C. H.; Dunn, Philip M.; Ayalew, Yeshi; Jenkinson, Donald H. (1996). "The Synthesis and Some Pharmacological Actions of the Enantiomers of the K+-Channel Blocker Cetiedil". Journal of Pharmacy and Pharmacology. 48 (8): 851–859. doi:10.1111/j.2042-7158.1996.tb03986.x.
  8. ↑ Ganellin, C. R.; Loynes, J. M.; Ridley, H. F.; Spickett, R. G. W. (1967). "Compounds Affecting the Central Nervous System. IV. Substituted 2-Benzyl-3-dialkylaminoalkylindenes and Related Compounds". Journal of Medicinal Chemistry. 10 (5): 826–833. doi:10.1021/jm00317a016.
  9. ↑ Bavin, P. M. G.; Ganellin, C; Loynes, J; Spickett, R G W (1969). "Compounds Affecting the Central Nervous System. V. Substituted 3-Dialkylaminoalkylindenes". Journal of Medicinal Chemistry. 12 (3): 513–516. doi:10.1021/jm00303a608.
  10. ↑ Jack David, Spickett Robert Geoffr William & Ganellin Charon Robin, US3159634 (1964 to Smith Kline and French Laboratories Ltd).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.